# A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential

> **NCT02706535** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 29 (actual)

## Conditions studied

- Drug Interactions
- Neoplasms

## Interventions

- **DRUG:** GSK525762 Besylate Tablets
- **DRUG:** Itraconazole 200 mg
- **DRUG:** Rifampicin 300 mg

## Key facts

- **NCT ID:** NCT02706535
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-05
- **Primary completion:** 2017-01-06
- **Final completion:** 2017-01-06
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2020-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02706535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02706535, "A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02706535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*